301-315 of 323
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
CME/CECurrent Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
CME/CECurrent and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Mamta Parikh, MD, MS
Daniel P. Petrylak, MD
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CEUtilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CETROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Benjamin Levy, MD
Rebecca Heist, MD, MPH
Peter Bela Illei, MD
Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
CME/CEImproved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
Ayse Tuba Kendi, MD
A. Oliver Sartor, MD
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
CME/CEEvolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
William Mencia, MD, FACEHP
Julie Blatt, MD
Taizo Nakano, MD
- advertisement
Jaffer Ajani, MD
Justin Gainor, MD
Sara A. Hurvitz, MD, FACP
Gopa Iyer, MD
Sara A. Hurvitz, MD, FACP
Sara A. Hurvitz, MD, FACP
Sara A. Hurvitz, MD, FACP
Justin Gainor, MD
Justin Gainor, MD
- advertisement
Justin Gainor, MD
Jaffer Ajani, MD
Gopa Iyer, MD
